The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Manuscripts of Pseudo-Apuleius's 5th-century work from the 10th and 11th centuries refer to the use of wild poppy Papaver agreste or Papaver rhoeas (identified as P. silvaticum) instead of P. somniferum for inducing sleep and relieving pain. The use of Paracelsus' laudanum was introduced to Western medicine in 1527, when Philippus Aureolus Theophrastus Bombastus von Hohenheim, better known by the name Paracelsus, claimed (dubiously) to have returned from wanderings in Arabia with a famous sword, within the pommel of which he kept "Stones of Immortality" compounded from opium thebaicum, citrus juice, and "quintessence of gold". The name "Paracelsus" was a pseudonym signifying him the equal or better of Aulus Cornelius Celsus, whose text, which described the use of opium or a similar preparation, had recently been translated and reintroduced to medieval Europe. The Canon of Medicine, the standard medical textbook that Paracelsus burned in a public bonfire three weeks after being appointed professor at the University of Basel, also described the use of opium, though many Latin translations were of poor quality. Laudanum was originally the 16th-century term for a medicine associated with a particular physician that was widely well-regarded, but became standardized as "tincture of opium", a solution of opium in ethanol, which Paracelsus has been credited with developing.
== In vitro activity == Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. Oritavancin demonstrates in vitro activity against both the planktonic and biofilmstates of staphylococci associated with prosthetic joint infection (PJI), albeit with increased minimum biofilm bactericidal concentration (MBBC) compared to Minimum inhibitory concentrations (MIC) values. Moreover oritavancin has demonstrated activity against in vitro to vancomycin-susceptible enterococci (VSE) and vancomycin-resistant enterococci (VRE) in both planktonic and biofilm states.
=== Human mutations === 341 mutations in human OTC have been reported. At least 259 of these mutations are considered to be disease-causing mutations. 149 of these mutations are known to cause onset of hyperammonemia during the first weeks of life. 70 manifest as hyperammonemia in male patients later in life. Most of the mutations occur in known functional motifs, such as the SMG loop or CP binding domains.
Sources: en.wikipedia.org
==== Sources ==== Formaldehyde (HCHO) enters the atmosphere via primary emission and secondary formation. Primary sources of atmospheric HCHO include direct biogenic emissions from vegetation and biomass burning, and anthropogenic emissions from vehicles, industrial activities, and coal combustion. Most atmospheric HCHO is secondary, produced by radical-driven oxidation of methane (CH4) and non-methane volatile organic compounds (VOCs) rather than direct emissions. Secondary production from CH4 oxidation dominates in remote and marine environments. Oxidation of biogenic and anthropogenic VOCs is the main source of HCHO in continental regions. Vegetation emits large amounts of isoprene, which is a key natural precursor of tropospheric formaldehyde over land.
=== Versions === The same scale has been validated in Spanish, Brazilian Portuguese, and Polish versions. A version has also been designed and validated for children. More recently, in September 2011, a modified version of the scale was validated using a criterion of self-assessment for ages six–eight years of age. A version of the scale was developed into a chart suitable for use on US television by Gary Kahan of NewYork–Presbyterian Hospital.
Stuart Hall (born 1929), a TV presenter convicted of indecent assault, lived in Wilmslow from 1958 to 2013 William Roache (born 1932) actor, plays Ken Barlow in Coronation Street since 1960; he has lived in Wilmslow for most of his adult life John Waite (born 1951), a presenter on British radio and TV, attended Wilmslow High School Barbara Wilshere (born 1959), an actress appearing in theatre, films and on TV, attended Wilmslow High School Jo Wheeler (born 1963), weather forecaster for Sky News, attended Wilmslow High School Fionnuala Ellwood (born 1964), an actress, portrayed Lynn Whiteley in the ITV soap Emmerdale, attended Wilmslow High School Miranda Sawyer (born 1967), journalist and broadcaster, and her brother Toby (born 1969), actor, grew up locally Chris Hawkins (born 1975), presenter and journalist, and his wife Clare Nasir (born 1970), meteorologist, have lived locally since 2012 Simon Gregson (born 1974), actor who plays taxi boss Steve McDonald in Coronation Street Ashley Taylor Dawson (born 1982), actor and singer, plays Darren Osborne in the Channel 4 soap opera Hollyoaks.
Sources: en.wikipedia.org
Uranium and thorium were the first actinides discovered. Uranium was identified in 1789 by the German chemist Martin Heinrich Klaproth in pitchblende ore. He named it after the planet Uranus, which had been discovered eight years earlier. Klaproth was able to precipitate a yellow compound (likely sodium diuranate) by dissolving pitchblende in nitric acid and neutralizing the solution with sodium hydroxide. He then reduced the obtained yellow powder with charcoal, and extracted a black substance that he mistook for metal. Sixty years later, the French scientist Eugène-Melchior Péligot identified it as uranium oxide. He also isolated the first sample of uranium metal by heating uranium tetrachloride with metallic potassium. The atomic mass of uranium was then calculated as 120, but Dmitri Mendeleev in 1872 corrected it to 240 using his periodicity laws. This value was confirmed experimentally in 1882 by K. Zimmerman. Thorium oxide was discovered by Friedrich Wöhler in the mineral thorianite, which was found in Norway (1827). Jöns Jacob Berzelius characterized this material in more detail in 1828. By reduction of thorium tetrachloride with potassium, he isolated the metal and named it thorium after the Norse god of thunder and lightning Thor. The same isolation method was later used by Péligot for uranium. Actinium was discovered in 1899 by André-Louis Debierne, an assistant of Marie Curie, in the pitchblende waste left after removal of radium and polonium. He described the substance (in 1899) as similar to titanium and (in 1900) as similar to thorium.
== Medical uses == Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.
In July 2009, Sovershenno Sekretno wrote that before the war, the hospital was deployed near South Ossetia while smaller group of military doctors were deployed to Abkhazia and asked "does it mean that intensive hostilities were not planned there [in Abkhazia]?" The newspaper noted that General Alexey Maslov was fired from the post of Commander-in-Chief of the Russian Ground Forces several days before the full-scale invasion of Georgia and some changes were related to the preparation of the war against Georgia. It quoted an unnamed Russian General Staff member as having said that "Some prepared the operation, while others came to sit on the ready laurels". The newspaper also wrote that the Russian Air Force was covering up the loss of one Sukhoi Su-24. The newspaper concluded that Russia needed South Ossetia as bridgehead for offensive operations. In November 2011, Stanislav Sadalsky commented on Medvedev's statement to have halted NATO expansion in 2008 that this was an admission that it was Medevedev who started the war, which was prosecutable under the Criminal Code of Russia.
=== Physiological factors === Physiological changes in nursing women, including an unusual milk supply and blocked milk ducts, cause nipple or breast ache. An oversupply of breast milk is caused by overactive milk expression. Hence, the excess milk accumulates, leading to breast engorgement and pain. On the other hand, milk supply will be lowered by prolonged breastfeeding, high pumping pressure and overly vigorous breast massage. Blocked milk ducts refers to lactiferous ducts' blockage at the nipple pore or deeper breast tissue. It hampers an adequate drainage of milk and causes breast mass, engorgement, redness, a nipple bleb and subsequent pain.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.